1
|
Pavlidis N, Nicolaides C, Bairaktari E, Kalef-Ezra J, Athanassiadis A, Seferiadis C, Fountzilas G. Soluble Interleukin-2 Receptors in Patients with Advanced Colorectal Carcinoma. Int J Biol Markers 2018; 11:6-11. [PMID: 8740635 DOI: 10.1177/172460089601100102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals served as controls. Seventy-five per cent of the patients had increased mean serum levels of sIL-2R (1539 ± 155 U/ml), while normal controls had mean levels of 555 ± 31 U/ml (p < 0.001). The relationship with hepatic or lymph nodal metastases showed no statistically significant difference (p=0.34 and p=0.47, respectively). Serum sIL-2R levels showed a linear correlation with CEA (p < 0.05). Patients with lower pretreatment sIL-2R levels (less than 1.200 U/ml) had a longer survival than patients with higher initial levels (more than 1.200 U/ml) (p=0.0049). In conclusion, the present work shows that the serum levels of sIL-2R: a) are elevated in patients with advanced colorectal cancer, b) have no relationship with the type of metastases, c) correlate with serum CEA and d) have a prognostic value for survival.
Collapse
Affiliation(s)
- N Pavlidis
- Department of Medicine, University of loannina, Greece
| | | | | | | | | | | | | |
Collapse
|
2
|
Pavlidis NA, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, Fountzilas G. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. Int J Biol Markers 2018; 10:75-80. [PMID: 7561242 DOI: 10.1177/172460089501000202] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The levels of soluble interleukin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was increased in 37 patients (71.2%). Comparison of these levels to those of normal controls showed a highly statistically significant difference (p<0.001). Serum sIL-2R levels were not related to histology, clinical stage or the presence of ascites (p-0.58, p=0.32 and p=0.67, respectively), nor did they follow disease activity or response to chemotherapy. However, patients with higher pretreatment sIL-2R levels (more than 1200 U/ml) were found to have a longer survival (p<0.02), possibly explained by the presence of activated lymphocytes and a better immune surveillance. We conclude that the serum level of sIL-2R: a) is elevated in ovarian cancer patients, b) has no relationship with histological subtypes, tumor burden or the presence of ascites, c) cannot serve as a valuable tumor marker for the monitoring of patient treatment, and d) has a prognostic value for survival.
Collapse
Affiliation(s)
- N A Pavlidis
- Department of Medicine, University of Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
3
|
Syrigos KN, Bacoyiannis C, Makatsoris T, Bamias A, Klouvas G, Nicolaides C, Boukovinas I, Linardou E, Fountzilas G, Kosmidis P. Paclitaxel versus oral vinorelbine in patients with advanced non-small cell lung cancer (NSCLC) with performance status (PS) 2: A randomized phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19035 Background: The optimal treatment of patients with advanced NSCLC and PS 2 is not well established. Our group has shown that single agent is equally effective to doublets. Purpose of this study was to compare efficacy and toxicity of two single agents Paclitaxel and oral Vinorelbine. Methods: 75 stage IIIb wet and IV chemotherapy-naïve for metastatic disease patients with PS 2 were randomized to either Paclitaxel 90mg/m2 weekly (group A: 36pts) or Vinorelbine 60mg/m2 weekly (group B: 34pts). Both agents were given for three weeks on and one week off. Results: A total of 70 out of 75 patients were eligible for analysis. All patient and disease characteristics were well balanced. Partial response rate (PR) was 14% (95% CI, 4.7%-29.5%) and 6% (95% CI, 0.7%- 19.7%) for groups A and B respectively. Stable disease (SD) was 17% (95% CI, 6.4%-32.8%) and 12% (95% CI, 3.3%-27.5%) respectively. These rates did not differ significantly. Median survival (OS) was 5.3m (95% CI, 3.1–7.5 m) and 3.5m (95% CI, 1.6 - 5.4 m) respectively (P=0.6). Progression free survival (PFS) was 3.2m (95% CI, 1.9 - 4.6 m) and 2.1m (95% CI, 1.8 - 2.3 m) respectively (P=0.2). There was a non-statistically significant trend for more myelotoxicity in the vinorelbine group. Conclusions: A trend for higher efficacy and less toxicity of Paclitaxel in comparison to oral Vinorelbine was observed, without however reaching statistical significance. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. N. Syrigos
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - C. Bacoyiannis
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - T. Makatsoris
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - A. Bamias
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - G. Klouvas
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - C. Nicolaides
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - I. Boukovinas
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - E. Linardou
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - G. Fountzilas
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| | - P. Kosmidis
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
| |
Collapse
|
4
|
Kosmidis P, Kalofonos H, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos M. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008; 19:115-22. [DOI: 10.1093/annonc/mdm430] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Kosmidis P, Kalofonos C, Syrigos K, Skarlos D, Fountzilas G, Nicolaides C, Bafaloukos D, Samantas E, Bakogiannis C, Dimopoulos A. O-094 Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable Non-small cell lung cancer (NSCLC). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80228-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Kosmidis PA, Kalofonos C, Syrigos K, Skarlos D, Fountzilas G, Nicolaides C, Bafaloukos D, Samantas E, Bakogiannis C, Dimopoulos AM. Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7000] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. A. Kosmidis
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - C. Kalofonos
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - K. Syrigos
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - D. Skarlos
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - G. Fountzilas
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - C. Nicolaides
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - D. Bafaloukos
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - E. Samantas
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - C. Bakogiannis
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| | - A. M. Dimopoulos
- Hygeia Hosp, Athens, Greece; Hosp of Patra, Patra, Greece; SOTIRIA Hosp, Athens, Greece; Errikos Dunan Hosp, Athens, Greece; Ahepa Hosp, Thessaloniki, Greece; Ioannina Hosp, Ioannina, Greece; Metropolitan Hosp, Piraeus, Greece; Agioi Anargyroi Hosp, Athens, Greece; Alexandra Hosp, Athens, Greece
| |
Collapse
|
7
|
Kosmidis PA, Dimopoulos MA, Syrigos C, Nicolaides C, Aravantinos G, Boukovinas I, Pectasides D, Bafaloukos D, Karina M, Kalofonos HP. Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. A. Kosmidis
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - M. A. Dimopoulos
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - C. Syrigos
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - C. Nicolaides
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - G. Aravantinos
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - I. Boukovinas
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - D. Pectasides
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - D. Bafaloukos
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - M. Karina
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| | - H. P. Kalofonos
- Hygeia Hospital, Athens, Greece; Alexandra Hospital, Athens, Greece; Sotiria Hospital, Athens, Greece; Ioannina Hospital, Ioannini, Greece; AG. Anargyroi, Athens, Greece; Theageneio, Thessalonikh, Greece; Metaxa, Pireaus, Greece; Metropolitan, Athens, Greece; AHEPA, Thessalonikh, Greece; Rio, Patra, Greece
| |
Collapse
|
8
|
Bacoyiannis C, Dimopoulos MA, Kalofonos HP, Nicolaides C, Aravantinos G, Bafaloukos D, Samelis G, Onyenadum A, Kiamouris C, Skarlos D, Pavlidis N, Triantafillidis A, Kosmidis P. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 2002; 63:130-8. [PMID: 12239447 DOI: 10.1159/000063806] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The aim of this study is firstly to determine the response rates and toxicity of two regimens containing vinblastine (VBL) in combination with interferon-gamma (IFN-gamma) in the treatment of patients with advanced renal cell carcinoma (RCC), and secondly to evaluate the additional efficacy of 13-cis retinoic acid (13-CRA) in RCC. METHODS Twenty-nine patients were included in the first trial (Trial 1) and 40 in the second one (Trial 2). The therapy given in Trial 1 consisted of VBL 0.15 mg/kg i.v. every 2 weeks and IFN-gamma 100 microg s.c. 3 times weekly. In Trial 2, the therapy consisted of the same two drugs, in the same doses, plus oral 13-CRA 40 mg/day. RESULTS In Trial 1 there were 3 (10.3%) patients with complete response, 3 (10.3%) patients with partial response, 8 (27.6%) patients with stable disease and 15 (51.7%) patients with progressive disease. In Trial 2, there was no complete response, however, 3 (7.5%) patients had partial response. Additionally, 15 (37.5%) patients maintained stable disease and 14 (35%) patients had progressive disease. In Trial 1, the median survival was 12.56 months (95% CI, 6.8-18.3, range 0.59-42.49) and the median time to progression was 3.21 months (95% CI, 1.7-4.7, range 0.03-42.49). In Trial 2, the median survival was 9.54 months (95% CI, 5.9-13.1, range 0.43-24.1) and the median time to progression was 3.9 months (95% CI, 0.8-7, range 0.26-24.1). In Trial 1, granulocytopenia grade 3 and 4 appeared in 5 (17.2%) patients and anaemia grade 3 in 1 (3.4%) patient. In Trial 2, there were grade 3 toxicities, as granulocytopenia in 5 (12.5%) patients, anemia in 4 (10.0%) patients, stomatitis in 3 (7.5%) patients, fatigue/malaise in 3 (7.5%) patients and 1 (2.5%) had diarrhea. No toxic deaths occurred in both studies. CONCLUSION The use of IFN-gamma does not enhance the low response of VBL-based chemotherapy. The additional administration of 13-CRA with the combination of VBL and IFN-gamma does not add to the efficacy of this combination in patients with advanced renal cell carcinoma. New active agents are needed to treat patients with this disease.
Collapse
Affiliation(s)
- C Bacoyiannis
- Medical Oncology Department, Hygeia Hospital, Athens, Greece. ParisKosmidis/Hygeia/
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Economopoulos T, Dimopoulos MA, Mellou S, Pavlidis N, Samantas E, Nicolaides C, Tsatalas C, Papadopoulos A, Papageogriou E, Papasavvas P, Fountzilas G. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol 2002; 68:135-43. [PMID: 12068793 DOI: 10.1034/j.1600-0609.2002.01620.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has less severe non-hematological toxicity. PATIENTS AND METHODS A randomized multicenter phase III study was conducted in order to compare the efficacy and toxicity of CEOP and CNOP in intermediate- and high-grade NHL. CEOP (arm A) consisted of cyclophosphamide 1000mg m(-2), vincristine 2mg, E 70mg m(-2) on day 1 and prednisone 60mg on days 1-7. The CNOP regimen (arm B) was identical to CEOP except for replacement of E by M at a dose of 12mg m(-2). Randomization was stratified according to stages I-IV. From September 1993 to March 1999, 249 patients registered for the trial. Patient characteristics were equally distributed in the two arms, except for age and International Prognostic Index (IPI) groups. RESULTS There were no significant differences between the two groups in the rates of complete (CR) and partial response (PR). The overall response rate was 78% in arm A (57% CR, 21% PR) and 82% in arm B (60% CR, 22% PR). With a median follow-up time of 47.3 months, the median survival was not reached in arm A, while it was 39.5 months in arm B (P=0.09). Three-year survival rates were 62.5% for CEOP and 51.5% for CNOP. There was no significant difference regarding the time to progression between the two groups (29.7 vs. 18.5 months); furthermore the median duration of CRs was 71.6 and 49 months for CEOP and CNOP, respectively (P=0.07). The therapeutic efficacies of both regimens were equivalent among the four IPI groups. More alopecia was observed in arm A. WHO grade >2 neutropenia was more frequent in arm B. Supportive treatment with G-CSF was given to 22 and 24 patients, respectively. CONCLUSION There were no significant differences in terms of overall response rates, overall survival and time to progression between CEOP and CNOP in the treatment of intermediate- and high-grade NHL. Patients with low or low intermediate IPI risk treated with either CEOP or CNOP showed significantly better survival, response rates and time to progression than those with high intermediate or high IPI risk. Therefore, new improved therapeutic approaches should be developed for the treatment of high IPI risk patients.
Collapse
Affiliation(s)
- T Economopoulos
- Second Department of Internal Medicine - Propaedeutic, Athens University, Evangelismos Hospital, Greece
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Bai M, Vlachonikolis J, Agnantis NJ, Tsanou E, Dimou S, Nicolaides C, Stefanaki S, Pavlidis N, Kanavaros P, Kanavarous P. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001; 14:1105-13. [PMID: 11706071 DOI: 10.1038/modpathol.3880444] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The expression of the cyclin-dependent kinase inhibitor (CDKI) p27 protein was investigated in relation to (1) the expression of the cell cycle regulators p53, Rb and p16 and (2) the proliferation profile as determined by the expression of Ki67, cyclin A, and cyclin B1 in 80 cases of de novo diffuse large B-cell lymphomas (DLBCL). P27 expression was low/null in large tumor cells in 58/80 cases and intermediate/high in 22/80 cases. Increased expression of p53 protein was observed in 39/80 cases. Decreased expression of Rb and p16 proteins was mutually exclusive and was observed in 5/80 and 14/80 cases, respectively. The analysis of the p27 expression status (low/null versus intermediate/high) with respect to the p53 and/or Rb/p16 expression status showed that low/null p27 expression was significantly correlated with increased p53 expression (P =.018) and showed a strong trend for correlation with concurrent increased p53 expression and decreased Rb or p16 expression (P =.050). These findings suggest a tendency for concurrent alterations of the cell cycle regulators p27, p53, and Rb or p16 in DLBCL, which might result in impaired tumor growth control. Indeed, the analysis of the combined p27/p53/Rb/p16 expression status with respect to the proliferation profile showed that (1) three alterations in the combined p27/p53/Rb/p16 status (i.e., low/null P27 expression, increased expression of p53, and decreased expression of Rb or p16) were significantly correlated with increased expression of cyclin B1 (P =.005) and (2) two or three alterations were significantly correlated with increased expression of cyclin A (P =.014). These findings suggest combined impairment of a complex cell-cycle control network involving the CDK inhibitor p27, the P53 pathway, and the Rb1 pathway, which exerts a cooperative effect resulting in enhanced tumor cell proliferation.
Collapse
Affiliation(s)
- M Bai
- Department of Pathology, Medical Faculty, University of Ioannina, 45110, Ioannina, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, Nicolaides C, Visvikis A, Dimopoulos MA. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2001; 12:1417-22. [PMID: 11762814 DOI: 10.1023/a:1012599307090] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE The aim of the study was to evaluate the efficacy and safety of the combination of gemcitabine and ifosfamide as a second-line treatment for advanced urothelial cancer. PATIENTS AND METHODS Thirty-four patients with metastatic urothelial cancer previously treated with cisplatin (CDDP)/ carboplatin (CBDCA) and/or taxanes-based chemotherapy were studied. Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna. every three weeks. Hematopoietic growth factors were given between days 3 to 5 and 12 to 16 to maintain the treatment schedule. RESULTS On an intent to treat basis, there was one complete response (CR) (3%) (95% confidence interval (95% CI): 0% to 10%) and six partial responses (PR) (18%) (95% CI: 7% to 34%). inducing an objective response rate (RR) of 21% (95% CI: 9% to 38%); 12 (35%) patients achieved a stable disease (SD) and 15 (44%) a progressive disease (PD). The median time to tumor progression (TTP) was four months (range, 0.52 to 21.6 months) and the median survival nine months (range 0.52 to 28 months). This regimen also provided the opportunity for symptomatic improvement of pain, dysuria, haematuria and leg oedema. Grade 3-4 neutropenia was experienced by 9 (27%) patients, grade 3 4 anemia by 6 (18%) and grade 3-4 thrombocytopenia by 4 (12%). Six patients were hospitalized due to febrile neutropenia. Despite the prophylactic use of hematopoietic growth factors, 8 (23.5%) patients required dose reduction due to myelosuppression. Grade 3 alopecia occurred in 14 (41%) patients, grade 3-4 nausea in 1 (3%), grade 2 fever in 3 (9%), grade 2-3 diarrhea in 2 ( 6%) and grade 2 allergic reaction in 1 (3%). CONCLUSION We conclude that the combination of gemcitabine and ifosfamide is an active salvage regimen for the treatment of urothelial cancer and that the treatment also has a tolerable toxicity profile; it warrants further investigation in combination with CDDP in chemotherapy-naïve patients.
Collapse
Affiliation(s)
- D Pectasides
- First Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus Greece.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37:1510-3. [PMID: 11506958 DOI: 10.1016/s0959-8049(01)00155-1] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P=0.05), LDL cholesterol (P<0.01) and apolipoprotein B levels (P=0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P<0.005) and LDL cholesterol/HDL cholesterol (P<0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile.
Collapse
Affiliation(s)
- M S Elisaf
- Department of Internal Medicine, Medical School, University of Ioannina, GR 451 10 Ioannina, Greece.
| | | | | | | | | | | | | |
Collapse
|
13
|
Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, Visvikis A, Skarlos D, Fountzilas G. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group. Anticancer Res 2001; 21:3005-10. [PMID: 11712802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Thirty-nine patients with advanced non-small cell lung cancer, refractory or resistant to platinum or taxanes derivatives were treated on an out-patient basis with vinorelbine 25 mg/m2 intravenous (I.V.) on days 1 and 8 followed by gemcitabine 800 mg/m2 l.V. on days 1 and 8. Chemotherapy was repeated every 3 weeks. The patients were evaluated for response every two cycles of treatment. All 39 patients were assessable for toxicity and 35 were assessable for response. On an intent to treat analysis, only 1 (2.6%) patient achieved a partial response (PR) (95% CI 0.09% to 17.6%); fourteen patients (35.9%, 95% CI 29.45% to 67.4%) had stable disease (SD) and 24 (61.5%) had progressive disease (PD). The median time to tumor progression (TTP) was 4.7 months (range 0.13 to 18.9 months), the median survival time was 7.3 months (range 0.6 to 18.9 months) and the 1-year survival rate was 35%. Clinical benefit response including improvement of PS, dyspnea and anorexia, pain and cough reduction and cessation of hemoptysis and fever was observed in 10% to 50% of patients. Grade 3/4 neutropenia occurred only in 2 (5.2%) patients. Five patients experienced febrile neutropenia, which was successfully treated with G-CSF and broad-spectrum antibiotics. No patient experienced grade 3/4 anaemia or thrombocytopenia. One patient experienced grade 4 fatigue and stopped the treatment. Nausea / vomiting, fatigue, neurotoxicity, diarrhea and fever were mild in the majority of patients and did not result in any clinically significant problem. There were no treatment-related deaths. In conclusion, the combination of gemcitabine and vinorelbine showed low objective response rate in patients previously treated with CDDP/taxanes-containing regimens. This regimen was relatively well-tolerated and was associated with prolonged 1-year survival and improvement in cancer related symptoms. To validate these findings a randomized trial of gemcitabine and vinorelbine versus taxotere or best supportive care is required.
Collapse
|
14
|
Fountzilas G, Papadimitriou C, Aravantinos G, Nicolaides C, Stathopoulos G, Bafaloukos D, Kalofonos H, Ekonomopoulos T, Skarlos D, Pavlidis N, Dimopoulos AM. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Oncology 2001; 60:214-20. [PMID: 11340372 DOI: 10.1159/000055321] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. From February 1995 until September 1997, 49 women with histologically confirmed breast cancer and > or =10 involved axillary nodes were treated postoperatively with three cycles of epirubicin (110 mg/m(2)) followed by three cycles of paclitaxel (250 mg/m(2) in a 3-hour infusion) followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m(2), methotrexate 57 mg/m(2), fluorouracil 840 mg/m(2); E-T-CMF). All cycles were repeated every 2 weeks with G-CSF support. Ovarian ablation with monthly injections of triptorelin for 1 year was performed in premenopausal patients and tamoxifen was prescribed for 5 years to all women with positive receptor status after the completion of chemotherapy. A total of 456 cycles of chemotherapy were administered, 363 (80%) of them at full dose. Forty-seven (96%) patients received all 9 cycles of chemotherapy. Relative dose intensity of epirubicin was 0.98, of paclitaxel 0.97, of cyclophosphamide 0.99, of methotrexate 0.98 and of fluorouracil 0.99. Grade 3--4 toxicities included anemia (8%), leukopenia (8%), peripheral neuropathy (6%), neutropenia (4%), thrombocytopenia (4%), stomatitis (2%), diarrhea (2%), fatigue (2%) and hypersensitivity reaction (2%). Febrile neutropenia occurred in 2 patients. Alopecia was universal. After a median follow-up of 3 years, 11 women (22%) relapsed and 4 (8%) died. The 3-year actuarial disease-free survival rate was 72% and the 3-year overall survival rate 90%. The E-T-CMF regimen is well tolerated, as adjuvant treatment, in patients with operable breast cancer with promising activity and deserves further evaluation in phase III studies.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Samantas E, Kalofonos H, Linardou H, Nicolaides C, Mylonakis N, Fountzilas G, Kosmidis P, Skarlos D. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol 2000; 11:1395-7. [PMID: 11142478 DOI: 10.1023/a:1026523316736] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE Although clinical experience with liposomal doxorubicin is still limited in solid tumours, single agent Caelyx (pegylated liposomal doxorubicin) treatment has shown promising results in AIDS-related Kaposi's sarcoma, metastatic breast and ovarian cancer and anecdotally in other solid tumours. This is the first report of its use in small-cell lung cancer (SCLC). The objective of this multicenter phase II study was to evaluate the safety, tolerance and anti-tumour activity of Caelyx as monotherapy in patients with recurrent SCLC. PATIENTS AND METHODS A total of 14 patients with recurrent SCLC who had not received prior treatment with doxorubicin, were accrued into this phase II study. All patients had progressed or relapsed after first-line chemotherapy. All but one had achieved objective responses to first-line treatment with median duration of five months (range 2-18 months) but half of them had experienced 'refractory' relapses (within 3-4 months). Study treatment consisted of Caelyx 50 mg/m2 (1-hour i.v infusion every 4 weeks for 6 cycles). RESULTS No responses were seen but in three patients disease was stabilised for a median of three months. The median number of cycles was 2 per patient, with 11 of 14 patients not completing 6 cycles of Caelyx treatment. From those, five patients were removed from the study after only one cycle due to rapid disease progression, and one was withdrawn after three cycles due to prolonged toxicity. Overall, treatment was well tolerated with no episodes of grade 4 toxicity and only two episodes of grade 3 toxicities: one of thrombocytopenia and one of prolonged palmar-plantar erythrodysesthesia (PPE). CONCLUSIONS These results demonstrate limited activity of Caelyx in this patient population, which may be related to the poor prognostic features of such patients. Our findings are in agreement with previous observations that doxorubicin-containing combinations are rarely active in platinum/etoposide failures. However, as in other studies the favourable toxicity profile of Caelyx is confirmed.
Collapse
Affiliation(s)
- E Samantas
- Agii Anargiri Cancer Hospital, Athens, Greece.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Fountzilas G, Nicolaides C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G, Aravantinos G, Pavlidis N. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 2000; 18:503-9. [PMID: 10923097 DOI: 10.3109/07357900009012188] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a median performance status of 1 (range, 0-2) were enrolled in the study. Treatment consisted of docetaxel 75 mg/m2 in a 1-hr infusion on day 1 preceded by gemcitabine 1000 mg/m2 over 30 min on days 1 and 8. One hundred eighty-one treatment cycles were administered, 113 (62.4%) of them at full dose. Relative dose intensity of gemcitabine and of docetaxel was 0.73 and 0.85, respectively. More common grade 3-4 toxicities included neutropenia (49%), anemia (10%), fatigue (10%), nausea/vomiting (8%), and alopecia (77%). Seven patients were hospitalized for febrile neutropenia. Granulocyte colony-stimulating factor (G-CSF) administration was required in 90% of patients. Overall, 14 patients (36%) responded, 3 (7.5%) of them completely. Median duration of response was 10.3 months (range, 4.6-17.5+). Median time to progression was 7 months (range, 0.2-17.5+) and median survival 12.7 months (range, 2-20.5+). In conclusion, the combination of docetaxel and gemcitabine, as used in the present study, has moderate activity in anthracycline-resistant ABC. Future studies should incorporate prophylactic administration of G-CSF to reduce the incidence of febrile neutropenia and maintain dose intensity.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristotle University of Thessaloniki, Macedonia, Greece
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2000; 11:873-5. [PMID: 10997817 DOI: 10.1023/a:1008361711049] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy. PATIENTS AND METHODS Thirty-one patients were treated with the combination of gemcitabine 1000 mg/m2 days 1 + 8 and vinorelbine 30 mg/m2 days 1 + 8. The cycles were repeated every three weeks. RESULTS Of 27 evaluable patients 1 (4%, 95% confidence interval (95% CI): 0.1%-19%) achieved complete remission (CR), five (18%; 95% CI: 6%-38%) partial remission (PR), eleven (40%; 95% CI: 22%-61%) stable disease and ten patients progressed. The median duration of response was six months (range 4-10+) and the median duration of disease stabilization was five months (range 2-22+). With a median follow-up of 16 months (range 0.4-22+) the median TTP was 3.5 months (range 0.4-22+) and the median survival was 9.5 months (range 0.4-22+). Grade 3-4 toxicities were granulocytopenia 15 patients (48%), rash 3 patients (10%), neuropathy 1 patient (3%) and thrombocytopenia 1 patient (3%). In conclusion the combination of gemcitabine/vinorelbine in the doses administered in this group of patients had a response rate of 22% and needs to be further evaluated in metastatic breast cancer.
Collapse
Affiliation(s)
- C Nicolaides
- Oncology Department, Ioannina University Hospital, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Fountzilas G, Stathopoulos G, Nicolaides C, Kalogera-Fountzila A, Kalofonos H, Nikolaou A, Bacoyiannis C, Samantas E, Papadimitriou C, Kosmidis P, Daniilidis J, Pavlidis N. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10:475-8. [PMID: 10370793 DOI: 10.1023/a:1008397424359] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown gemcitabine to be highly active in SCCHN cell lines. PURPOSE OF THE STUDY To evaluate the activity and toxicity of the combination of paclitaxel by three-hour infusion and gemcitabine as first-line chemotherapy in patients with recurrent and/or metastatic head and neck cancer (HNC). PATIENTS AND METHODS From September 1996 until May 1998, 44 patients with non-nasopharyngeal recurrent and/or metastatic HNC entered the study. There were 37 men and seven women with a median age of 61 years (range 35-79) and a median performance status of 1 (range 0-2). The location of the primary tumor in the majority of them was either the larynx or the oral cavity. Treatment consisted of six cycles of gemcitabine 1100 mg/m2 over 30 min on days 1 and 8 immediately followed on day 1 by paclitaxel 200 mg/m2 by three-hour infusion. The treatment was repeated every three weeks. RESULTS Twenty-four (55%) patients completed all six cycles of treatment. A total of 205 cycles were administered, 165 (81%) of them at full dose. The median relative dose intensity (DI) of gemcitabine was 0.93 and of paclitaxel 0.95. Except for alopecia, which was universal, grade 3-4 toxicities included neutropenia (21%), thrombocytopenia (5%), anemia (5%), infection (5%), flu-like syndrome (5%) and peripheral neuropathy (2%). Five (11%) patients achieved complete and 13 (30%) partial responses, for an overall response rate of 41%. After a median follow-up of 13 months, the median time to progression was four months and median survival nine months. CONCLUSIONS The combination of paclitaxel and gemcitabine is active and well tolerated in patients with recurrent and/or metastatic HNC-randomized studies comparing this combination with other regimens are warranted.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristotle University of Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Fountzilas G, Nicolaides C, Aravantinos G, Skarlos D, Kosmidis P, Papakostas P, Stathopoulos GP, Kontostolis E, Bafaloukos D, Pavlidis N. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study. Oncology 1998; 55:508-12. [PMID: 9778614 DOI: 10.1159/000011903] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Forty-one patients with operable breast cancer and >/=10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A total of 240 cycles were administered, all of them at full dose and 19 (8%) with a delay. Thirty-eight (93%) patients completed the treatment according to the protocol. The relative dose intensity of epirubicin was 0.99. Grade 3 toxicities included anemia (3%), nausea and vomiting (5%) and alopecia (71%). After a median follow-up of 40 months, 16 (39%) patients were free of relapse. In conclusion, the present study has shown that the administration of dose-dense chemotherapy with epirubicin is feasible in the adjuvant setting with minimal toxicity.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristotle University of Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P, Pectasides D, Karabelis A, Giannakakis T, Symeonidis A, Papadopoulos A, Antoniou F, Pavlidis N. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998; 55:405-15. [PMID: 9732217 DOI: 10.1159/000011886] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently formulated. We tried to identify the clinical prognostic factors that predict treatment outcome in Greek patients with diffuse large cell lymphomas and validated the IPI in these patients. The possible prognostic variables for tumor response, relapse-free (RFS) and overall survival (OS) were analyzed in 239 consecutive patients treated with anthracycline-based chemotherapy regimens. In univariate analysis, factors associated with poor response were stages III-IV, performance status (PS) >/=2, spleen and bone marrow involvement, more than one extranodal site involved, increased lactate dehydrogenase (LDH) value, hemoglobin (Hb) <12 g/dl, albumin <3.5 g/dl, erythrocyte sedimentation rate (ESR) >50 mm/h. Multivariate analysis identified stage, PS, more than one extranodal site involved, increased LDH level, and ESR > 50 mm/h as the factors more predictive of poor response. For RFS, multiple Cox analysis found stages III-IV and bone marrow involvement to be statistically significant. For OS, multiple Cox analysis identified stage III-IV, PS >/=2, bone marrow involvement, more than one extranodal site involved, increased LDH level and ESR > 50 mm/h as negative prognostic factors. Patients stratified in the different risk groups of the IPI had a significantly different outcome regarding complete response (CR) rate, RFS and OS. In conclusion, although age >60 years was not recognized as an adverse factor in this analysis, our patients stratified in the different groups of the IPI had significant differences in CR rate, 2-year RFS and OS verifying the prognostic significance of the index. Bone marrow involvement and ESR > 50 mm/h, parameters that are not included in the IPI, adversely affected survival.
Collapse
Affiliation(s)
- C Nicolaides
- Department of Ioannina University Hospital, Ioannina, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D. First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998; 9:1031-4. [PMID: 9818080 DOI: 10.1023/a:1008466928323] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first-line chemotherapy in patients with advanced breast cancer (ABC). BACKGROUND Paclitaxel is an active agent in ABC. Furthermore, our group has shown that the combination of paclitaxel and carboplatin is effective in anthracycline-resistant ABC. PATIENTS AND METHODS From January 1996 until March 1997, 66 women with ABC were treated with paclitaxel (175 mg/m2) by three-hour infusion followed by carboplatin at an AUC of 6 mg x min/ml every three weeks. The median age of the patients was 56 years (range 28-75). A total of 39 patients had received adjuvant chemotherapy and 22 of them were treated with an anthracycline or mitoxantrone-containing regimen. RESULTS A total of 324 cycles (median: six) were administered, 273 (85%) of them at full dose. The median number of delivered cycles was six. The median delivered dose intensity (DI) of paclitaxel was 55.1 mg/m2/week (range 30.5-69.3) and the relative DI was 0.95 (range 0.5-1.2). Eight patients (12%, 95% confidence interval (CI): 5%-22%) achieved complete and 28 (42%, 95% CI: 30%-55%) partial responses. Grade 3-4 toxicities included anemia (5%), granulocytopenia (24%), thrombocytopenia, nausea/vomiting and allergic reaction (3% each), myalgias/arthralgias and neurotoxicity (1.5% each). Febrile neutropenia occurred in eight (12%) patients. Alopecia was universal. After a median follow-up of 17.3 (range 0.07-24.5) months, 48 (72%) patients have demonstrated tumor progression and 24 (36%) have died. Median time to progression was 8.6 (range 0.07-23+) months and median survival 20.4 (range 0.07-24.5+) months. CONCLUSIONS The combination of paclitaxel and carboplatin has moderate activity in ABC and can be easily delivered on an outpatient basis with manageable toxicity. This regimen may be useful especially in patients to whom anthracyclines or cisplatin administration is precluded because of other concomitant diseases.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristotle University of Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, Skarlos D, Nicolaides C, Pavlidis N. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998; 18:1907-14. [PMID: 9677443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analyzed the tissue expression of the protein products of the apoptosis modulation genes p53 and bcl-2 in 47 CUP cases. Formalin-fixed, paraffin embedded tumor specimens were stained with commercially available antibodies to p53 (DO7) and bcl-2 after antigen retrieval by the microwave method. Staining was evaluated by intensity (1+ to 3+), percentage of positive cells (1-100%), and the 'intensity times percentage' product defined as the immunoreactivity index with values ranging from 0 to 300. Immunoreactivity index values higher than 150 were considered to characterize protein over-expression. Expression of p53 was identified in 70.2% of tumors while 53% of them showed a high immunoreactivity index. Bcl-2 expression was detected in 65% of tumors and overexpressed in 40%. Overexpression of both proteins was detected in 20% of tumors. The detection of either protein was not associated with any of the major clinicopathological variables studied. Nevertheless, a trend towards a more favourable response to platin based chemotherapy was seen in the cases that showed a strong expression of both proteins, when analysed by immunoreactivity index and percentage of positive cells. We conclude that CUP overexpress at a high percentage the p53 and the bcl2 proteins. The observed weak association of strong expression of these proteins with response to platin-based chemotherapy deserves further evaluation in the CUP setting.
Collapse
Affiliation(s)
- E Briasoulis
- Department of Medicine, Medical School, Ioannina University, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Nicolaides C, Giannakakis T, Skarlos D, Athanassiadis A, Fountzilas G, Damigos D, Pavlidis N. Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin. J Exp Clin Cancer Res 1998; 17:71-75. [PMID: 9646236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Tropisetron is a novel selective antagonist of the type-3 serotonin (5-HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of > 100 mg/m2 has a high emetogenic potential. This study was designed to determine whether a single intravenous administration of tropisetron could prevent acute nausea and vomiting in patients treated with high dose epirubicin. Forty chemotherapy naive breast cancer patients treated with epirubicin at a dose of 110 mg/m2 on an outpatient basis were enrolled in the study. Tropisetron 5 mg i.v. was used as antiemetic prophylaxis. "On demand" treatment with tropisetron 5 mg p.os was used for the rescue of patients who failed on the initial i.v. dose. Complete control of acute nausea and vomiting had 62.5% (95% C.I. 47.2-77.8), partial control 15% (95% C.I. 3.8-26.2) and 22.5% (95% C.I. 9.3-35.7) insufficient control or failure. Headache was the most common adverse event reported in 3 patients (7.5%) and constipation in 2 patients (5%). Interestingly, patients with a negative experience of nausea and vomiting during pregnancy and those treated for metastatic disease, had a better control of chemotherapy-induced nausea and vomiting. In conclusion, a single 5 mg i.v. dose of tropisetron is safe and effective in preventing acute emesis in patients treated with high dose epirubicin.
Collapse
Affiliation(s)
- C Nicolaides
- Oncology Section, Ioannina University Hospital, Greece
| | | | | | | | | | | | | |
Collapse
|
24
|
Fountzilas G, Athanassiades A, Papadimitriou V, Dimopoulos MA, Bafaloukos D, Aravantinos G, Nicolaides C, Kalofonos H, Papakostas P, Xiros N, Razi E. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology (Williston Park) 1998; 12:45-8. [PMID: 9516604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
In a phase II study, 66 patients with advanced breast cancer (median age 56 years; range, 28 to 75 years) were treated with paclitaxel (Taxol), 175 mg/m2 infused over 3 hours, and carboplatin (Paraplatin), dosed to attain an area under the concentration-time curve (AUC) of 6 mg x min/mL; treatment was repeated every 3 weeks. A total of 38 (58%) patients had received prior adjuvant chemotherapy, 21 with a regimen containing an anthracycline or mitoxantrone (Novantrone). As of May 1997, 295 cycles of paclitaxel-carboplatin have been administered, 248 (84%) at full dose. The relative dose intensity of paclitaxel is 0.9 (range, 0.5 to 1.2). Of the 66 patients, 8 (12%) have achieved a complete response and 27 (41%) a partial response, for a total response rate of 53%. Grade 3 to 4 toxicities have included anemia (5%), leukopenia (25%), thrombocytopenia (5%), nausea/vomiting (7%), myalgias/arthralgias (4%), allergic reaction, neurotoxicity, and infection (2% each). Alopecia has been universal. Median time to progression is 8.9 months; median survival has not yet been reached. We conclude that the combination of paclitaxel and carboplatin has significant activity in advanced breast cancer and can easily be administered on an outpatient basis with manageable toxicity.
Collapse
Affiliation(s)
- G Fountzilas
- AHEPA Hospital, Aristole University of Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Bacoyiannis C, Dimopoulos M, Nicolaides C, Aravantinos G, Xiros N, Skarlos D, Pavlidis N, Kosmidis P. Phase II study of interferon gamma (rIFN-G) and vinblastine(VBL) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84565-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Nicolaides C, Klouvas G, Fountzilas G, Athanassiadis A, Skarlos D, Samantas E, Kosmidis P, Mylonakis N, Pavlidis N. Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group Study (HeCOG). J Exp Clin Cancer Res 1997; 16:91-4. [PMID: 9148868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether an intensified dose-carboplatin could yield a better response. Carboplatin at a dose of 450 mg/m2 dose in combination with vindesine 3 mg/m2 every three weeks and GM-CSF support was used in a phase II study to treat 44 patients with non-small cell lung cancer (NSCLC). As compared to our previous study carboplatin dose intensity was increased from 75 mg/m2/wk to 150 mg/m2/wk. Six patients (13.6%) responded to treatment and all were partial responders. The median duration of response was 5 months (range 1.5-9 month). After a retrospective analysis a dose response effect was not evident at different carboplatin AUC doses. Twenty patients (45.45%) experienced thrombocytopenia and seventeen patients (38.6%) anemia as major toxicities. This study shows that in NSCLC a dose-response effect does not exist between carboplatin dose intensification and response rate cannot be traced.
Collapse
Affiliation(s)
- C Nicolaides
- Dept. of Medicine, University of Ioannina, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996; 19:459-64. [PMID: 8823487 DOI: 10.1097/00000421-199610000-00007] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15,3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and carcinoembryonic antigen (CEA); 141 (67.5%) were free of recurrence and 68 (32.5%) developed metastases during the follow-up. The mean values of tested tumor markers differed significantly in those with progressive disease compared with those free of disease recurrence. The sensitivity of tumor markers were CA 15-3, 68.2%; CEA, 34.1%; MCA, 72.7%; and TPA, 72.7%. The combination of CA 15-3 with TPA or MCA with TPA showed a trend for improved sensitivity of both markers (p = 0.06), with no specific loss of specificity (p = 0.11). The addition of CEA to CA 15-3 or MCA does not provide additional information for clinical evaluation. Patients with elevated tumor marker determinations had significantly shorter survival than those with values within the normal range. Two serial, progressively increasing values of tumor markers during the follow-up strongly predict recurrence. This study indicates that the comeasurement of CA 15-3 with TPA or MCA with TPA is justifiable in monitoring breast cancer patients postoperatively.
Collapse
Affiliation(s)
- D Pectasides
- First Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Grecce
| | | | | | | | | | | |
Collapse
|
28
|
Elisaf M, Bairaktari E, Nicolaides C, Fountzilas G, Tzallas C, Siamopoulos K, Tsolas O, Pavlidis N. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 1996; 16:2725-8. [PMID: 8917378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
It has recently been suggested that increased lipoprotein (a) levels are an independent risk factor for coronary heart disease. It has also been reported that tamoxifen can induce changes in blood lipid values. In this prospective study we investigated the long term effects tamoxifen on the lipid profile, focusing on lipoprotein (a) levels. Thirty-eight postmenopausal women with breast cancer treated with tamoxifen at a dose of 20 mg daily were studied. The mean age was 61 years. Serum lipoprotein (a) levels and lipid parameters (total cholesterol, high and low density lipoprotein cholesterol, triglycerides, apolipoprotein A-I and B) were measured after an overnight fast on the 1, 3, 6 and 9 month of tamoxifen treatment. A progressive fall in median lipoprotein(a) levels from 8 mg/dl to 3 mg/dl (p < 0.001) was observed. In addition, a significant decrease in the total and low density lipoprotein cholesterol and in apolipoprotein B, as well as an increase in apolipoprotein A-l were also noticed. It is concluded that our data on serum lipoprotein(a) levels agree with the beneficial anti-atherogenic effects of tamoxifen administration on lipoproteins.
Collapse
Affiliation(s)
- M Elisaf
- Department of Internal Medicine, University Hospital, University of Ioannina, Medical School, Greece
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Pavlidis N, Nicolaides C, Athanassiadis A, Beriatou K, Skarlos D, Giannakakis T, Kosmidis P, Karvounis N, Fountzilas G. Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study. Oncology 1996; 53:159-62. [PMID: 8604243 DOI: 10.1159/000227553] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Preclinical data have shown a synergism between 5-fluorouracil and interferon-gamma against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. 5-Fluorouracil was administered as an intravenous bolus of 500 mg/m2 weekly and interferon-gamma subcutaneous injection at a dose of 200 micrograms (6 x 10(6) IU) 3 times a week. Thirty-two patients were evaluable for response. There was one complete and two partial responses (response rate 9.0%, 95% CI 1.98-25.02%). Eleven patients (34%) had stable disease. Common toxicities included fever 81%, nausea/vomiting 19%, diarrhea 16%, flu-like syndrome 16%, malaise 12.5% and leukopenia 12.5%. These results indicate that the above combination of 5-fluorouracil and interferon-gamma has an unimpressive activity in patients with advanced colorectal carcinoma. Toxicity was very tolerable.
Collapse
Affiliation(s)
- N Pavlidis
- Oncolocy Section, Department of Medicine, University of Ioannina, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Pavlidis N, Bairaktari E, Nicolaides C, Kalef-Ezra J, Athanassiadis A, Seferiadis C, Fountzilas G. 1271 The role of soluble interleukin-2 (SIL-2R) receptors as a tumor marker in patients with advanced colorectal cancer (ACC). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96517-h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Pavlidis N, Nicolaides C, Klouvas G, Briassoulis E. Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature. J Chemother 1994; 6:417-22. [PMID: 7699431 DOI: 10.1080/1120009x.1994.11741177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The main purpose of this trial was to investigate the activity of a less toxic regimen in patients with advanced gastric carcinoma regarding response rate and survival. We report on a pilot study of 20 patients treated with the combination of 5-fluorouracil and folinic acid. 5-fluorouracil was administered at a daily dose of 450 mg/m2 followed by folinic acid 200 mg/m2 for four consecutive days every four weeks. The overall response rate was 15% with one complete and two partial responders. The median duration of response was 11, 10 and 10 months respectively. The median survival of all patients was 9 months. Toxicity was mild and consisted primarily of diarrhea. Stomatitis and myelosuppression occurred rarely. In conclusion, the combination of 5-fluorouracil and folinic acid has moderate activity in gastric cancer, while median survival appears similar to the other more intensive regimens. The combination is very well tolerated with minimal toxicity. A detailed review of the literature regarding the effectiveness of the above regimens on response rate, overall survival and toxicity is also presented.
Collapse
Affiliation(s)
- N Pavlidis
- Department of Medicine, School of Medicine, University of Ioannina, Greece
| | | | | | | |
Collapse
|
32
|
Pavlidis NA, Klouvas G, Nicolaides C, Karantanas A, Beer M, Fountzilas G. A phase II trial of carboplatin and vindesine in patients with non-small cell lung cancer. A Hellenic Cooperative Oncology Group study. Lung Cancer 1993; 10:85-9. [PMID: 8069607 DOI: 10.1016/0169-5002(93)90312-l] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In an effort to investigate a regimen less toxic and more convenient than cisplatin combinations, 50 patients with non-small cell lung cancer (NSCLC) were treated in a Phase II study with carboplatin and vindesine. Carboplatin 300 mg/m2 every 28 days and vindesine 3 mg/m2 every 2 weeks were administered on an outpatient basis. Eight patients had a partial response of their disease (16%, confidence limits 7-29%). Mean duration of response was 4.5+ months (1 +/- 8). Toxicity, mainly of grade I-II, was noticed in 4-28% of the patients. The most common side effect was mild to moderate leukopenia (28%). The combination of carboplatin and vindesine at the above doses was very well tolerated. Although the response rate was relatively low, the survival in this patient population was similar to other cisplatin-containing regimens.
Collapse
Affiliation(s)
- N A Pavlidis
- Department of Medicine, University of Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
33
|
|